Ladenburg Thalmann analyst Robert LeBoyer started Outlook Therapeutics with a Buy rating and $9 price target. The analyst expects the shares to be driven by the company's clinical trial progress for ONS-5010 in wet age-related macular degeneration and the other indications.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here